Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Amgen (NASDAQ:AMGN) had its target price upped by equities research analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00 in a research report issued on Thursday,MarketScreener reports. The firm presently has a “hold” rating on the medical research company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential downside of 23.22% from the stock’s previous close.

A number of other research firms have also weighed in on AMGN. Royal Bank Of Canada increased their price objective on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday. Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Argus raised their price target on shares of Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Guggenheim boosted their price objective on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $351.65.

Amgen Stock Up 4.5%

Shares of NASDAQ:AMGN opened at $384.20 on Thursday. The stock has a market capitalization of $206.88 billion, a P/E ratio of 27.00, a price-to-earnings-growth ratio of 3.73 and a beta of 0.46. The stock’s 50-day moving average price is $334.45 and its 200-day moving average price is $311.45. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78. Amgen has a 12-month low of $261.43 and a 12-month high of $385.12.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the company posted $5.31 EPS. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen will post 20.62 earnings per share for the current year.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amgen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Associated Banc Corp lifted its holdings in shares of Amgen by 1.0% during the fourth quarter. Associated Banc Corp now owns 23,515 shares of the medical research company’s stock valued at $7,697,000 after purchasing an additional 223 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Amgen by 2.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 19,555 shares of the medical research company’s stock worth $6,401,000 after buying an additional 423 shares during the last quarter. New Millennium Group LLC increased its position in Amgen by 49.1% during the 4th quarter. New Millennium Group LLC now owns 629 shares of the medical research company’s stock valued at $206,000 after buying an additional 207 shares in the last quarter. Delta Financial Advisors LLC increased its position in Amgen by 4.1% during the 4th quarter. Delta Financial Advisors LLC now owns 10,301 shares of the medical research company’s stock valued at $3,372,000 after buying an additional 407 shares in the last quarter. Finally, Americana Partners LLC raised its stake in Amgen by 31.4% during the fourth quarter. Americana Partners LLC now owns 17,085 shares of the medical research company’s stock valued at $5,592,000 after buying an additional 4,081 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.